Clinical Trial Update: A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluated GL-ONC1, an oncolytic vaccinia virus, in patients with advanced peritoneal carcinomatosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peritoneal Carcinomatosis

Drugs mentioned

• GL-ONC1

Snippet

Sponsor: Genelux GmbH | Conditions: Peritoneal Carcinomatosis | Phase 1, Phase 2 | Status: COMPLETED